Samyang Biopharm USA
Samyang Biopharm is a healthcare company focused on medical devices, pharmaceuticals, and gene therapeutics. The company develops and manufactures bioabsorbable polymer-based medical devices (notably surgical sutures and related biosurgery products), cytotoxic anticancer active pharmaceutical ingredients and finished dosage forms, and nucleic-acid delivery platforms for gene therapeutics. It emphasizes R&D, open innovation partnerships, GMP-compliant production, and sustainability/ESG governance for global markets.
Industries
Nr. of Employees
medium (51-250)
Products
Bioabsorbable surgical sutures (PGA/PDO and other polymers)
Absorbable suture materials and finished suture products designed for wound closure and minimally invasive surgery, including barbed and antibacterial variants.
Hemostatic and anti-adhesion biosurgery products
Biodegradable hemostatic agents and anti-adhesion products developed using oxidized regenerated cellulose and polymer technologies for surgical applications.
Polycaprolactone-based dermal filler (PCL microspheres in CMC gel)
Dermal filler for aesthetic correction composed of biodegradable PCL microspheres in a water-soluble gel carrier (carboxymethylcellulose).
Absorbable aesthetic threads (PDO-based)
Polydioxanone (PDO)-based aesthetic threads in multiple formats (mono, screw, barbed) for minimally invasive facial lifting procedures.
Transdermal patch products
Transdermal patch products designed to deliver active substances through the skin for systemic or localized effects.
Cytotoxic anticancer APIs and finished injections
APIs and injectable finished dosage forms for oncology indications; exports of APIs to Europe and Japan are noted.
Bioabsorbable surgical sutures (PGA/PDO and other polymers)
Absorbable suture materials and finished suture products designed for wound closure and minimally invasive surgery, including barbed and antibacterial variants.
Hemostatic and anti-adhesion biosurgery products
Biodegradable hemostatic agents and anti-adhesion products developed using oxidized regenerated cellulose and polymer technologies for surgical applications.
Polycaprolactone-based dermal filler (PCL microspheres in CMC gel)
Dermal filler for aesthetic correction composed of biodegradable PCL microspheres in a water-soluble gel carrier (carboxymethylcellulose).
Absorbable aesthetic threads (PDO-based)
Polydioxanone (PDO)-based aesthetic threads in multiple formats (mono, screw, barbed) for minimally invasive facial lifting procedures.
Transdermal patch products
Transdermal patch products designed to deliver active substances through the skin for systemic or localized effects.
Cytotoxic anticancer APIs and finished injections
APIs and injectable finished dosage forms for oncology indications; exports of APIs to Europe and Japan are noted.
Services
Collaborative R&D, licensing and joint development focused on nucleic-acid therapeutics and delivery technologies; seeks partners with expertise in nucleic-acid vaccines/therapies, novel polymers/lipids and process development.
Collaborative R&D, licensing and joint development focused on nucleic-acid therapeutics and delivery technologies; seeks partners with expertise in nucleic-acid vaccines/therapies, novel polymers/lipids and process development.
Expertise Areas
- Biodegradable polymer development
- Surgical suture design and manufacturing
- Cytotoxic anticancer API and injection production
- Nucleic-acid delivery and gene therapy platforms
Key Technologies
- Biodegradable polymers (glycolide, lactide, p-dioxanone, polycaprolactone)
- Lipid–polymer nanoparticle delivery systems
- Ionizable lipid design for tissue-selective delivery
- Nanoparticle formulation libraries
News & Updates
Company states it holds the top global market share in suture bulk thread (>50%).
Company history records selection of biodegradable suture as a world-class product in 2019.
Company established a U.S. subsidiary in 2018 as part of global expansion.
Company states it holds the top global market share in suture bulk thread (>50%).
Company history records selection of biodegradable suture as a world-class product in 2019.
Company established a U.S. subsidiary in 2018 as part of global expansion.